Cannabinoids Explained: THC, CBD, CBN, CBG, Delta-8 and the Whole Family (2026)

Cannabinoids are a family of compounds that act on the body's endocannabinoid system (ECS). Your body makes its own cannabinoids (called endocannabinoids), and the cannabis plant makes its own version, called phytocannabinoids — the ones in this guide. There are also fully lab-made synthetic cannabinoids, which are a separate and riskier category we mostly leave aside here.

The two best-studied receptors are CB1 (concentrated in the brain and central nervous system) and CB2 (more common in immune tissue). How strongly a cannabinoid activates CB1 is the single biggest predictor of whether it feels intoxicating. THC is a strong CB1 activator, which is why it's psychoactive. CBD interacts with the system very differently and doesn't produce that high.

A quick vocabulary note: psychoactive and intoxicating are not perfect synonyms. Technically CBD is mildly psychoactive in that it can affect mood, but it is non-intoxicating — it won't impair you. Throughout this guide we use "intoxicating" to mean the impairing, high-producing effect most people mean when they ask "will this get me high?"

If you remember one thing, make it this. Delta-9 THC and CBD are nearly identical in chemical formula but behave like opposites in the body.

Delta-9 THC is the classic intoxicating cannabinoid — the reason cannabis is federally controlled and the compound dispensaries measure potency by. It's a strong CB1 agonist, producing euphoria, relaxation, altered time perception, increased appetite and, in some people at higher doses, anxiety or paranoia.

CBD (cannabidiol) is non-intoxicating. It doesn't activate CB1 the way THC does, so it won't get you high. It's widely reported to be associated with feelings of calm and is studied for a range of uses, though for most consumer products the strong human evidence is still limited. The one clear, FDA-recognized exception is a purified prescription CBD medicine approved for certain rare seizure disorders — a reminder that "CBD" on a store shelf and CBD studied in a clinic are not the same thing.

The honest one-liner: THC is the one that gets you high, CBD is the one that doesn't, and almost every other cannabinoid is a variation on that theme.

Here's a fact that surprises a lot of people: fresh, raw cannabis is barely intoxicating. That's because the plant doesn't actually make much THC directly — it makes THCA (tetrahydrocannabinolic acid), an acidic precursor that doesn't fit CB1 receptors well and won't get you high.

To unlock THC, you need heat. The reaction is called decarboxylation ("decarbing") — heat knocks a carboxyl group off the molecule, turning THCA into THC. This happens instantly when you light a joint or hit a vaporizer, and more slowly in an oven (roughly 230–250°F / 110–121°C for about 30–40 minutes) when making edibles. Skip the decarb step in home edibles and they simply won't work.

The same thing happens on the CBD side: the plant makes CBDA, which decarboxylates into CBD, though it's slightly more heat-resistant. This is why "raw cannabinoid" juices and tinctures (THCA, CBDA) exist as a distinct, non-intoxicating category — and why a product labeled "THCA flower" can be sold as non-intoxicating on the shelf but becomes ordinary THC the moment you smoke it. That detail matters legally and practically.

Several cannabinoids will impair you, just to different degrees. Where they get complicated is how they're made and how they're regulated.

Delta-9 THC — the benchmark. The main intoxicating compound in marijuana, present in meaningful amounts in the plant.

Delta-8 THC — an isomer of delta-9 (same atoms, slightly different bond placement). It is genuinely intoxicating but commonly described as somewhat milder than delta-9. Critically, delta-8 occurs only in trace amounts in the plant, so commercial delta-8 is almost always manufactured by chemically converting hemp-derived CBD. That manufacturing route is central to its legal story (next section) and to quality concerns — poorly made products can carry leftover reaction byproducts.

Delta-10 THC — another isomer, also typically made by converting hemp CBD, and generally reported as milder/less potent than delta-8.

HHC (hexahydrocannabinol) — a semi-synthetic cannabinoid made by hydrogenating (adding hydrogen to) hemp-derived THC, the same kind of chemistry that turns oil into margarine. It's intoxicating, with potency commonly estimated to sit between delta-8 and delta-9. Hydrogenation makes it more shelf-stable, but "semi-synthetic" means it's a lab-modified product, not something you'd extract from a bud.

For all of these converted/semi-synthetic cannabinoids, the honest caveat is the same: human safety and long-term data are limited, and product quality varies widely because much of the market has operated with little testing oversight.

Beyond THC and CBD sits a roster of "minor" cannabinoids that brands increasingly market. The honest summary: they're interesting, mostly non-intoxicating or mild, and the human evidence is genuinely early. Most of what we know comes from lab and animal studies, not large clinical trials.

CBG (cannabigerol) — often called the "mother cannabinoid" because its acidic form, CBGA, is the precursor the plant uses to build THC and CBD. Non-intoxicating. Studied in preclinical models for inflammation and other pathways; human data is limited.

CBC (cannabichromene) — non-intoxicating. Investigated mostly in lab settings (it's been studied alongside other minors for anti-inflammatory activity in cell models). Very little human research exists.

CBN (cannabinol) — forms as THC ages and oxidizes, which is why old cannabis is higher in CBN. It's at most mildly intoxicating (much weaker than THC) and is heavily marketed as a "sleep" cannabinoid, though the human evidence for that specific claim is thin and often rests on the THC and terpenes it's bundled with.

THCV (tetrahydrocannabivarin) — the trickiest to label. At low doses it can actually blunt some THC effects, while at higher doses it appears to have intoxicating potential of its own. So calling THCV flatly "non-psychoactive" isn't accurate; its behavior is dose-dependent. It's often discussed in the context of appetite, but that's an area of ongoing research, not a settled fact.

Across this whole group, be wary of confident health claims. As researchers have noted, marketing language for minor cannabinoids has tended to run ahead of what clinical trials can actually support.

Use this as a quick reference. "Intoxicating?" reflects the typical, decarbed/finished form a consumer would encounter. "Commonly reported for" lists what people associate these with or what's being studied — not proven medical uses.

The entourage effect is the hypothesis that cannabis compounds — cannabinoids plus terpenes (the aromatic oils) — produce a fuller, modulated experience when taken together than any single isolated molecule does alone. In plain terms: the idea that "full-spectrum" extract behaves differently than pure THC.

There's real plausibility here — many of these compounds touch overlapping receptors and pathways, and CBD is widely thought to soften some of THC's sharper edges. But it's important to be straight about the evidence: the entourage effect is a well-supported hypothesis, not a fully proven mechanism. Much of the strongest data is preclinical, and rigorous human trials isolating these interactions are still limited. It's a useful framework for understanding why a whole-plant product can feel different from an isolate — just not a license for sweeping health claims.

This is the part people get wrong most often, so let's be precise and neutral.

The 2018 Farm Bill (the Agriculture Improvement Act of 2018) removed "hemp" from the federal definition of marijuana, defining hemp as cannabis containing no more than 0.3% delta-9 THC by dry weight. Crucially, that cap named only delta-9. That wording created the gray area: entrepreneurs reasoned that intoxicating cannabinoids made from hemp — delta-8, delta-10, HHC, high-THCA flower — could be sold as "hemp" as long as the delta-9 number stayed under 0.3%, even if the product was plainly intoxicating. That's how delta-8 became a nationwide convenience-store product while remaining federally ambiguous and inconsistently regulated.

States never agreed. Some banned delta-8 and similar products outright, some regulated them, and some left them untouched — producing a true patchwork where the same product is legal in one state and prohibited across the border.

Then the definition changed. In November 2025, federal legislation (Public Law 119-37) redefined hemp around total THC rather than just delta-9, and added a very low cap on THC per package for finished consumable products. Because that threshold is so low, it is expected to sweep in the large majority of intoxicating hemp-derived products currently sold at retail — edibles, beverages, vapes, gummies and the like. The law includes a transition period (reported as roughly one year, into late 2026) before the new restrictions take full effect, and details, enforcement and possible further changes were still developing as of early 2026.

The practical takeaway: the hemp-derived-THC loophole that defined the delta-8 era is closing at the federal level, but the timeline and on-the-ground enforcement are in flux. Meanwhile, state-legal marijuana programs (the dispensary system) operate on a completely separate legal track. None of this is legal advice — if you buy, sell or travel with any of these products, check your current state law and the latest federal status first.

A few honest, practical habits that hold up regardless of which cannabinoid you're looking at:

• Match the cannabinoid to your goal. Want a high? You're looking at THC (delta-9), or to a lesser degree delta-8/HHC. Want to avoid impairment? CBD, CBG and CBC are your non-intoxicating options.
• "Hemp-derived" does not mean "won't get you high." Delta-8, delta-10 and HHC are all hemp-derived and all intoxicating. The source plant tells you about legality history, not about effects.
• Look for a current third-party lab report (a COA). For converted cannabinoids especially, a Certificate of Analysis from an independent lab — checking potency and contaminants — is the single best quality signal. No COA is a red flag.
• Treat health claims skeptically. If a minor-cannabinoid product promises specific medical outcomes, that language is almost always running ahead of the evidence. "Studied for" and "reported to" are honest; "treats" and "cures" are not.
• Start low. Potency between products is wildly inconsistent in unregulated corners of the market. A small dose and patience beats a guess.